EZH2 mutations and overexpression of core PRC2 subunits have been found in multiple solid cancers, including prostate and breast cancer, as well as in hematological malignancies (Comet et al., 2016; Chan and Morey, 2019). Here, EZH2 is linked to breast carcinoma.